Close menu




November 12th, 2019 | 06:36 CET

AURORA, BEVCANNA, CANOPY OR EXMCEUTICALS - WHICH CANNABIS SHARE HAS POTENTIAL?

  • Cannabis
Photo credits: pixabay.com

The shares of Canadian cannabis companies have lost significant value this year. There are exceptions, such as BevCanna and EXMceuticals, but the well-known players such as Aurora and Canopy have fallen significantly. This was preceded by a period of price rises and forecasts that never seemed to end. In the meantime, the phase of speculation is over and it is all about facts. Speculators go out and investors stand on the sidelines and observe the development or already use the chance to enter.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA05156X1087

Table of contents:


    AURORA SHARE LOST MORE THAN 60%.

    The shares of Aurora and Canopy have lost significant value this year. The shares of Aurora changed hands this year at the top of the Canadian home stock exchange at CAD 13.67. The shares of Aurora have lost a lot of value this year. On yesterday's trading day, the stock was sold at 4.78 CAD. The low for the year so far was 4.58 CAD. At the peak of the hype in 2018, the share was still listed at CAD 16.74. The current market value is CAD 4.88 billion.

    WHEN WAS THE BOTTOM FOUND AT CANOPY?

    The development is similar for the industry giant Canopy. The company's shares peak in 2019 at 70.99 CAD. In the previous year even a price of 76.68 CAD was reached. Size also does not protect this title from a price correction and in the meantime the share is listed close to the low for the year of 25.00 CAD. Yesterday, the share was sold at 26.85 CAD. Canopy's market value has thus shrunk to CAD 9.35 billion.

    STOCK EXCHANGE DEBUTANTS OFFER ALTERNATIVE

    Meanwhile, the situation at BevCanna and EXMceuticals looks more relaxed, but this is certainly also due to the size of the two companies. BevCanna is a producer of cannabis drinks and, like CBD producer EXMceuticals, celebrated its stock market debut this year. The two companies were thus spared the hype in 2018 and the share price trend is thus calmer - without massive setbacks. The company value of BevCanna amounts to about 20.93 million CAD with a share price of 0.44 CAD.

    At yesterday's closing price of CAD 1.00, EXMceuticals reported a stock market value of CAD 36.55. The company's share price was around CAD 20.93 million. Jonathan Summers is Chairman of EXMceuticals and will present the company to investors at this year's German Equity Forum of Deutsche Börse AG in Frankfurt from 25 to 27 November 2019.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read

    Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

    Ayurcann, Novavax, Covestro - The stragglers are coming!

    • Cannabis

    Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

    Read

    Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

    Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

    • Cannabis

    About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

    Read